BPC-157 demonstrated 45–51% intramuscular bioavailability in six beagle dogs and was well tolerated across the doses tested, with no adverse findings reported.
VIEW SOURCE ↗
EXPERIMENTAL PEPTIDES SHOWN HERE ARE IN DEVELOPMENT AND NOT AVAILABLE FOR SALE · MOBILITY COLLAGEN IS A NUTRITIONAL SUPPLEMENT, NOT A VETERINARY MEDICINE · REGULATORY STATUS IS PRODUCT-SPECIFIC · ALWAYS CONSULT YOUR VETERINARIAN
Every claim on our product pages carries an evidence level. This library is the full record: the studies, the market benchmarks, and the honest gaps. Bring it to your vet — we encourage that.
CANINE DATA
Published studies in dogs: randomized controlled trials or pharmacokinetic studies. The strongest signal available in veterinary science.
PRECLINICAL / COMMUNITY
Rodent or in-vitro studies, or widespread veterinary-community practice without controlled canine trials. Promising, unproven in dogs.
HONESTY NOTE
Where evidence is missing or regulatory status is unresolved, we say so explicitly — on every product, every time.
THE FULL RECORD
BPC-157 demonstrated 45–51% intramuscular bioavailability in six beagle dogs and was well tolerated across the doses tested, with no adverse findings reported.
VIEW SOURCE ↗
In a 2024 randomized, placebo-controlled trial of 31 dogs with osteoarthritis, daily bioactive collagen peptides (PETAGILE®) produced statistically significant improvement in objective force-plate gait measures over 12 weeks versus control.
VIEW SOURCE ↗
Undenatured type-II collagen (UC-II) matched the NSAID robenacoxib on force-plate outcomes in canine osteoarthritis studies — a rare head-to-head against a registered veterinary drug.
αs1-casozepine, a milk-derived peptide, showed placebo-controlled calming effects in both cats and dogs across multiple veterinary behavior trials.
The tripeptide KPV reduced intestinal inflammation in mouse models of colitis via PepT1-mediated uptake. No canine trials have been published — we grade this accordingly.
The BPC-157 + TB-500 pairing ('Wolverine stack') is widespread in US pet products (e.g. Protex Pets: BPC-157 250mcg + TB-500 100mcg, $64.99/30 servings). TB-500 has no published canine efficacy trials; this pairing is community practice, not proven therapy.
Loyal (loyal.com) is running the largest canine aging study in history — 1,317 dogs enrolled across 70 US veterinary practices — validating that pet owners will invest in longevity science for their animals.
VIEW SOURCE ↗
US pet peptide retail pricing of $99–$149/month (Integrative Peptides PetTides) and mainstream media coverage (Men's Health, 2026) indicate established, growing demand — at prices Peptides4Pets will undercut locally.



THE FULL PICTURE
No pet peptide product — from PSA or any competitor — is approved by the FDA or SAHPRA. Our products are in development and are not veterinary medicines. They are not intended to diagnose, treat, cure or prevent any disease. Evidence levels vary by compound, and we label them honestly. Always consult your veterinarian before starting your pet on any supplement.
EXPERIMENTAL PEPTIDES SHOWN HERE ARE IN DEVELOPMENT AND NOT AVAILABLE FOR SALE · MOBILITY COLLAGEN IS A NUTRITIONAL SUPPLEMENT, NOT A VETERINARY MEDICINE · REGULATORY STATUS IS PRODUCT-SPECIFIC · ALWAYS CONSULT YOUR VETERINARIAN